EUVIMEDEUVIMED entdecken
VergleichsstudieValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Implementation of an Automated Lipoprotein(a) Assay on a Third-Party Automated Analyzer: Validation, Method Comparison, and Clinical Impact of Formula-Based Mass-to-Molar Conversion

Nerea Sainz-Pastor iD, Silvia Camos Anguila, Miriam Albéniz Abaigar iD, Ana Molina, Helena Castellà, Marc Delgado, José Luis Bedini, Rebeca Muñoz, Emilio Ortega, Naira Rico

The Journal of Applied Laboratory Medicine · 04.11.2026 · 11 (6) · 1350-1363

DOI: 10.1093/jalm/jfag122 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Applied Laboratory Medicine, online erschienen am 19.08.2026. Verfasst von Nerea Sainz-Pastor und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio CORE, Servicio de Bioquímica y Genética Molecular, CDB, Hospital Clínic de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Lipoprotein(a). Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lipoprotein(a) [Lp(a)] is an independent, genetically determined cardiovascular risk factor. Although consensus recommends reporting Lp(a) in molar units using assays with minimized apolipoprotein(a) [apo(a)] isoform size–related bias, some laboratories still use mass units with conversion formulas of uncertain reliability. This study describes the first adaptation and validation of the Roche Tina-quant® Lp(a) Gen.2 assay [TQ-Lp(a)] on the Atellica Solution platform, including method comparison and evaluation of formula-based mass-to-molar conversion.

Methods

A total of 126 serum samples were analyzed using 3 approaches: Roche TQ-Lp(a) as the molar comparator method, adapted Atellica-TQ-Lp(a), and native Siemens Lp(a) on Atellica CH, which reports results in mg/dL. Siemens mass-based results were converted to nmol/L using the manufacturer’s equation. Analytical performance was assessed according to Spanish Society of Laboratory Medicine recommendations. Method comparison included Passing–Bablok regression, Bland–Altman, and Cohen κ at clinically relevant thresholds.

Results

Atellica-TQ-Lp(a) demonstrated acceptable precision (CV <6%), excellent linearity (r = 0.99), and adequate sensitivity (limit of quantification, 8 nmol/L). No relevant interference was observed, and stability was maintained for 4 days under refrigerated and frozen conditions. Agreement with the comparator method was high (slope, 0.99; intercept, 3.9 nmol/L; r = 0.99), with minimal constant bias and high categorical concordance (weighted κ = 0.98). In contrast, formula-derived values showed proportional bias (slope, 1.27), moderate agreement (weighted κ = 0.78), and frequent upward reclassification at ≥125 nmol/L.

Conclusions

The Roche Tina-quant® Lp(a) Gen.2 assay can be implemented on Atellica CH to report Lp(a) in nmol/L with high analytical comparability to the Roche/cobas implementation. Fixed mg/dL-to-nmol/L conversion formulas introduce systematic bias and clinically relevant misclassification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein(a)HumansReproducibility of ResultsAutomation, LaboratoryCardiovascular Diseases

Substanzen

Lipoprotein(a)

Autor:innen und Institutionen

  • Laboratorio CORE, Servicio de Bioquímica y Genética Molecular, CDB, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Servicio de Análisis Clínicos, Laboratorio Clínic Territorial ICS-IAS Girona, Hospital Universitari Doctor Josep Trueta, Girona, Spain.
  • Servicio de Endocrinología y Nutrición, Hospital Clínic Barcelona, Barcelona, Spain.
  • CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.

ORCID-Profile: Nerea Sainz-Pastor, Miriam Albéniz Abaigar

Zitieren

APA

Sainz-Pastor, N., Camos Anguila, S., Albéniz Abaigar, M., Molina, A., Castellà, H., Delgado, M., Bedini, J. L., Muñoz, R., Ortega, E., & Rico, N. (2026). Implementation of an Automated Lipoprotein(a) Assay on a Third-Party Automated Analyzer: Validation, Method Comparison, and Clinical Impact of Formula-Based Mass-to-Molar Conversion. The Journal of Applied Laboratory Medicine, 11(6), 1350-1363. https://doi.org/10.1093/jalm/jfag122

Vancouver

Sainz-Pastor N, Camos Anguila S, Albéniz Abaigar M, Molina A, Castellà H, Delgado M, et al. Implementation of an Automated Lipoprotein(a) Assay on a Third-Party Automated Analyzer: Validation, Method Comparison, and Clinical Impact of Formula-Based Mass-to-Molar Conversion. The Journal of Applied Laboratory Medicine. 2026;11(6):1350-1363. doi:10.1093/jalm/jfag122

BibTeX
@article{SainzPastor2026,
  author = {Sainz-Pastor, Nerea and Camos Anguila, Silvia and Albéniz Abaigar, Miriam and Molina, Ana and Castellà, Helena and Delgado, Marc and Bedini, José Luis and Muñoz, Rebeca and Ortega, Emilio and Rico, Naira},
  title = {Implementation of an Automated Lipoprotein(a) Assay on a Third-Party Automated Analyzer: Validation, Method Comparison, and Clinical Impact of Formula-Based Mass-to-Molar Conversion},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2026},
  volume = {11},
  number = {6},
  pages = {1350--1363},
  doi = {10.1093/jalm/jfag122}
}
Kostenlos starten →